PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2018; 07(02): 118-122
DOI: 10.4103/sajc.sajc_116_18
Original Article

Practical consensus recommendations on Her2 +ve breast cancer with solitary brain mets

Nitesh Rohatgi
Department of Medical Oncology, Max Hospital, New Delhi
,
A. Munshi
Department of Radiation Oncology, Fortis Hospital, Gurugram, Haryana
,
P. Bajpai
Department of Medical Oncology, Manipal Super Specialty Hospital, New Delhi
,
M. Singh
Department of Medical Oncology, Mahavir Cancer Sansthan, Patna, Bihar
,
S. Sahai
Department of Radiation Oncology, Fortis Hospital, Gurugram, Haryana
,
M. Ahmad
Department of Radiation Oncology, Jolly Grant Himalayan Institute, Dehradoon, Uttarakhand
,
K. Singh
Department of Radiation Oncology, MAMS, New Delhi
,
H. Singh
Department of Radiaton Oncology, Action Balajee Cancer Center, New Delhi
,
Purvish M. Parikh
Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra
,
S. Aggarwal
Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi
› Institutsangaben
Financial support and sponsorship: Nil.
› Weitere Informationen
Auch verfügbar aufeRef
 als PDF herunterladen Lizenzen und Reprints
Preview

Abstract

Breast cancer is a common cause of brain metastases, with metastases occurring in at least 10–16% of patients. Longer survival of patients with metastatic breast cancer and the use of better imaging techniques are associated with an increased incidence of brain metastases. Current therapies include surgery, whole-brain radiation therapy, stereotactic radiosurgery, chemotherapy and targeted therapies. However, the timing and appropriate use of these therapies is controversial and careful patient selection by using available prognostic tools is extremely important. Expert oncologist discussed on the mode of treatment to extend the OS and improve the quality of life ofHER2-positivebreast cancer patients with Solitary brain metastases. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.

Key words

Herceptin - stereotactic radiosurgery - surgery - TDM1 - WBCR


Publikationsverlauf

Artikel online veröffentlicht:
22. Dezember 2020

© 2018. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913-20.
  • 2 Lin NU. Breast cancer brain metastases: New directions in systemic therapy. Ecancermedicalscience 2013;7:307.
  • 3 Lin NU, Winer EP. Brain metastases: The HER2 paradigm. Clin Cancer Res 2007;13:1648-55.
  • 4 Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: A retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol 2013;14:244-8.
  • 5 Aversa C, Rossi V, Geuna E, Martinello R, Milani A, Redana S, et al. Metastatic breast cancer subtypes and central nervous system metastases. Breast 2014;23:623-8.
  • 6 Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the international breast cancer study group (IBCSG). Ann Oncol 2006;17:935-44.
  • 7 Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006;24:5658-63.
  • 8 Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006;107:696-704.
  • 9 Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the international breast cancer study group (IBCSG). Ann Oncol 2006;17:935-44.
  • 10 Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008;10:R20.
  • 11 Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X, et al. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neurooncol 2013;112:467-72.
  • 12 Leone JP, Lee AV, Brufsky AM. Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. Cancer Med 2015;4:989-94.
  • 13 Lee SS, Ahn JH, Kim MK, Sym SJ, Gong G, Ahn SD, et al. Brain metastases in breast cancer: Prognostic factors and management. Breast Cancer Res Treat 2008;111:523-30.
  • 14 Ogawa K, Yoshii Y, Nishimaki T, Tamaki N, Miyaguni T, Tsuchida Y, et al. Treatment and prognosis of brain metastases from breast cancer. J Neurooncol 2008;86:231-8.
  • 15 Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2012;82:2111-7.
  • 16 Gil-Gil MJ, Martinez-Garcia M, Sierra A, Conesa G, Del Barco S, González-Jimenez S, et al. Breast cancer brain metastases: A review of the literature and a current multidisciplinary management guideline. Clin Transl Oncol 2014;16:436-46.
  • 17 Niwi ska A, Pogoda K, Murawska M, Niwi ski P. Factors influencing survival in patients with breast cancer and single or solitary brain metastasis. Eur J Surg Oncol 2011;37:635-42.
  • 18 National Cancer Registry Programme, Indian Council of Medical Research. Leading sites of cancer. In: Consolidated Report of Population Based Cancer Registries 2001 2004, Incidence and Distribution of Cancer. Bangalore: Coordinating Unit, National Cancer Registry Programme (ICMR); 2006. p. 8 30.
  • 19 Badwe RA, Gangawal S, Mitra I, Desai PB. Clinico pathological featuresand prognosis of breast cancer in different religious communities in India. Indian J Cancer 1990;27:220 8.
  • 20 Altekruse SF, Kosary CL, Krapcho M, editors. SEER Cancer Statistics Review. ???: National Cancer Institute; 1975 2007.
  • 21 National Cancer Registry Program. Ten Year Consolidated Report of the Hospital Based Cancer Registries, 1984–1993, An Assessment of the Burden and Care of Cancer Patients. New Delhi: Indian Council of Medical Research; 2001.
  • 22 Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg 2007;31:1031-40.
  • 23 Mahmoud-Ahmed AS, Suh JH, Lee SY, Crownover RL, Barnett GH. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: A retrospective study. Int J Radiat Oncol Biol Phys 2002;54:810-7.
  • 24 Kirsch DG, Ledezma CJ, Mathews CS, Bhan AK, Ancukiewicz M, Hochberg FH, et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 2005;23:2114-6.
  • 25 Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 2009;100:894-900.
  • 26 Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: Incidence, survival, and risk factors. Oncologist 2007;12:766-73.
  • 27 Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30:419-25.
  • 28 Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-7.
  • 29 Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American society of clinical oncology clinical practice guideline. J Clin Oncol 2014;32:2100-8.
  • 30 Rorive A, Collignon J, Martin M, André C, Jerusalem G, Coucke P, et al. Breast cancer and brain metastases. Rev Med Liege 2011;66:299-305.
  • 31 Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500.
  • 32 Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994;29:711-7.
  • 33 Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996;78:1470-6.
  • 34 Tabouret E, Metellus P, Gonçalves A, Esterni B, Charaffe-Jauffret E, Viens P, et al. Assessment of prognostic scores in brain metastases from breast cancer. Neuro Oncol 2014;16:421-8.
  • 35 Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 1998;280:1485-9.
  • 36 Badiyan SN, Regine WF, Mehta M. Stereotactic radiosurgery for treatment of brain metastases. J Oncol Pract 2016;12:703-12. Coffey RJ, Lunsford LD. Stereotactic radiosurgery using the 201 cobalt-60 source gamma knife. Neurosurg Clin N Am 1990;1:933-54.
  • 37 Coffey RJ, Lunsford LD. Stereotactic radiosurgery using the 201 cobalt-60 source gamma knife. Neurosurg Clin N Am 1990;1:933-54.
  • 38 Mack A, Czempiel H, Kreiner HJ, Dürr G, Wowra B. Quality assurance in stereotactic space. A system test for verifying the accuracy of aim in radiosurgery. Med Phys 2002;29:561-8.
  • 39 Adler JR Jr., Chang SD, Murphy MJ, Doty J, Geis P, Hancock SL, et al. The cyberknife: A frameless robotic system for radiosurgery. Stereotact Funct Neurosurg 1997;69:124-8.
  • 40 Chang SD, Main W, Martin DP, Gibbs IC, Heilbrun MP. An analysis of the accuracy of the cyberKnife: A robotic frameless stereotactic radiosurgical system. Neurosurgery 2003;52:140-6.
  • 41 Yu C, Main W, Taylor D, Kuduvalli G, Apuzzo ML, Adler JR Jr., et al. An anthropomorphic phantom study of the accuracy of cyberknife spinal radiosurgery. Neurosurgery 2004;55:1138-49.
  • 42 Yu C, Jozsef G, Apuzzo ML, Petrovich Z. Dosimetric comparison of cyberKnife with other radiosurgical modalities for an ellipsoidal target. Neurosurgery 2003;53:1155-62.
  • 43 Collins SP, Coppa ND, Zhang Y, Collins BT, McRae DA, Jean WC, et al. CyberKnife radiosurgery in the treatment of complex skull base tumors: Analysis of treatment planning parameters. Radiat Oncol 2006;1:46.
  • 44 Flickinger JC, Lunsford LD, Wu A, Maitz AH, Kalend AM. Treatment planning for gamma knife radiosurgery with multiple isocenters. Int J Radiat Oncol Biol Phys 1990;18:1495-501.
  • 45 Leith JT, Cook S, Chougule P, Calabresi P, Wahlberg L, Lindquist C, et al. Intrinsic and extrinsic characteristics of human tumors relevant to radiosurgery: Comparative cellular radiosensitivity and hypoxic percentages. Acta Neurochir Suppl 1994;62:18-27.
  • 46 Wowra B, Muacevic A, Tonn JC. Quality of radiosurgery for single brain metastases with respect to treatment technology: A matched-pair analysis. J Neurooncol 2009;94:69-77.
  • 47 Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 2011;29:134-41.
  • 48 Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study. Lancet Oncol 2014;15:387-95.
  • 49 Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American society for radiation oncology evidence-based guideline. Pract Radiat Oncol 2012;2:210-25.
  • 50 Minniti G, Esposito V, Clarke E, Scaringi C, Lanzetta G, Salvati M, et al. Multidose stereotactic radiosurgery (9 gy × 3) of the postoperative resection cavity for treatment of large brain metastases. Int J Radiat Oncol Biol Phys 2013;86:623-9.
  • 51 Kaal EC, Niël CG, Vecht CJ. Therapeutic management of brain metastasis. Lancet Neurol 2005;4:289-98.
  • 52 Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 2006;295:2483-91.
  • 53 Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 2011;29:134-41.
  • 54 Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 2009;10:1037-44.
  • 55 Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, et al. A European organisation for research and treatment of cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: Quality-of-life results. J Clin Oncol 2013;31:65-72.
  • 56 Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 2007;25:1260-6.
  • 57 Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007;68:1388-95.
  • 58 Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, et al. Breast cancer with brain metastases: Clinicopathologic features, survival, and paired biomarker analysis. Oncologist 2015;20:466-73.
  • 59 Koo T, Kim IA. Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: From biology to treatment. Radiat Oncol J 2016;34:1-9.
  • 60 Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87:586-92.
  • 61 Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 2009;100:894-900.